SARS-CoV-2 vaccine based on vesicular stomatitis virus exhibits high neutralizing efficacy against variants
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera - ScienceDirect
Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity - ScienceDirect
VSV Tools
Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction - Cytotherapy
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera - ScienceDirect
Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera
Frontiers SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
PDF) Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Syncytia Formation Promotes Virus Resistance to Interferon and Neutralizing Antibodies
JCI - Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach, Virology Journal
